Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Acamprosate→

Acamprosate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
77337-76-9
Molecular formula
C5H11NO4S
Molecular weight
181.21 g/mol
Drug class
Glutamatergic/GABAergic neuromodulatorsynthetic taurine analogue used in alcohol-dependence relapse prevention
Mechanism of action
The exact mechanism by which acamprosate supports maintenance of abstinence is not fully understood. Experimental data suggest modulation of glutamatergic (particularly NMDA-related) and GABAergic neurotransmission during alcohol withdrawal-related neuroadaptation; these pathways should be presented as proposed rather than confirmed clinical targets.
Indications / reported uses
  • Maintenance of alcohol abstinence in adults with alcohol dependence who are abstinent when treatment is initiated; use as part of a comprehensive psychosocial treatment programme. It does not treat acute alcohol withdrawal.

Sources: US DailyMed — Acamprosate calcium prescribing information · UK SmPC — Acamprosate 333 mg gastro-resistant tablets · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Acamprosate Environmental Risk Assessment (ERA) (the Acamprosate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.